Time filter

Source Type

Patent
Shenzhen Salubris Pharmaceuticals Co. | Date: 2017-03-29

The present invention provides an allisartan isoproxil solid dispersion with high drug loading and stability. On that basis, it also provides an allisartan isoproxil pharmaceutical composition containing mentioned solid dispersion. Compared with available technologies, the mentioned allisartan isoproxil pharmaceutical composition is characterized by high stability, good dissolution performance, and improved patient compliance, etc.


Disclosed are polymorph of allisartan isoproxil and a pharmaceutical composition thereof. The polymorph is non-electrostatic, highly flowable and highly stable, and can be used for treating hypertension and complications thereof.


Patent
Shenzhen Salubris Pharmaceuticals Co. | Date: 2017-05-10

An allisartan isoproxil solid dispersion, pharmaceutical composition comprising the same and use thereof. The Allisartan Isoproxil solid dispersion consists of Allisartan Isoproxil and a pharmaceutically acceptable carrier material, the carrier material comprising a solubilizing carrier and a surfactant, the mass ratio of Allisartan Isoproxil to the surfactant being 1:0.010.10.


Patent
Shenzhen Salubris Pharmaceuticals Co. | Date: 2015-05-20

The present invention provides an allisartan isoproxil solid dispersion with high drug loading and stability. On that basis, it also provides an allisartan isoproxil pharmaceutical composition containing mentioned solid dispersion. Compared with available technologies, the mentioned allisartan isoproxil pharmaceutical composition is characterized by high stability, good dissolution performance, and improved patient compliance, etc.


Patent
Shenzhen Salubris Pharmaceuticals Co. | Date: 2015-06-30

An allisartan isoproxil solid dispersion, pharmaceutical composition comprising the same and use thereof. The Allisartan Isoproxil solid dispersion consists of Allisartan Isoproxil and a pharmaceutically acceptable carrier material, the carrier material comprising a solubilizing carrier and a surfactant, the mass ratio of Allisartan Isoproxil to the surfactant being 1:0.010.10.


Patent
Shenzhen Salubris Pharmaceuticals Co., Shandong Salubris Pharmaceuticals Co. and Huizhou Salubris Pharmaceuticals Co. | Date: 2016-10-03

To provide a Clopidogrel Hydrogen Sulfate solid preparation, melting granulation process is used, the content of raw material in the granules obtained is high, and the preparation is of good homogeneity, smooth surface, small tablet weight variation and dissolution complying with the clinical medication. When specific crystal form is used, the effect is better.


The present invention belongs to the field of pharmaceutical technology and relates to salt of polypeptide vaccine, preparation method therefor, and pharmaceutical preparation comprising said salt, in particular to KIFGSLAFL acetate, its preparation method and pharmaceutical preparations containing such acetate.


The present invention relates to an amorphous allisartan isoproxil which is an angiotensin II receptor blocker with good flowability and a large bulk density and with no obvious electrostatic phenomenon; the find of the amorphous allisartan isoproxil can effectively reduce the generation of dust pollution during the production, thereby providing convenience the production of allisartan isoproxil. The present invention also relates to a pharmaceutical composition containing the amorphous allisartan isoproxil. The pharmaceutical composition is highly stable, and allisartan isoproxil formulation prepared from the pharmaceutical composition can effectively ensure the quality of the drug.


The present invention belongs to the field of pharmaceutical technology and relates to salt of polypeptide vaccine, preparation method therefor, and pharmaceutical preparation comprising said salt, in particular to KIFGSLAFL acetate, its preparation method and pharmaceutical preparations containing such acetate.


The present invention relates to an amorphous allisartan isoproxil which is an angiotensin II receptor blocker with good flowability and a large bulk density and with no obvious electrostatic phenomenon; the find of the amorphous allisartan isoproxil can effectively reduce the generation of dust pollution during the production, thereby providing convenience the production of allisartan isoproxil. The present invention also relates to a pharmaceutical composition containing the amorphous allisartan isoproxil. The pharmaceutical composition is highly stable, and allisartan isoproxil formulation prepared from the pharmaceutical composition can effectively ensure the quality of the drug.

Loading Shenzhen Salubris Pharmaceuticals Co. collaborators
Loading Shenzhen Salubris Pharmaceuticals Co. collaborators